RDHL - Redhill Biopharma Ltd logo

Redhill Biopharma Ltd

RDHL

RedHill Biopharma Ltd. specializes in developing and commercializing treatments for gastrointestinal and infectious diseases. Key products include Talicia for H. pylori infection and Aemcolo for travelers' diarrhea, alongside a diverse clinical pipeline.

⚕️ Healthcare NASDAQ Listed 2013 $ USD
$1,000 invested 10 years ago →$0today

Score Overview

1 Year
Score
Net Growth-381.70%
Net TrendShrank
Net Income Consistency—
Rev Growth7x
Rev TrendGrew
Revenue Consistency—
5 Years
Score5.1
Net Growth97.89%
Net Trend60%
Net Income Consistency—
Rev Growth-97.62%
Rev Trend40%
Revenue Consistency—
10 Years
Score
Net Growth92.96%
Net Trend40%
Net Income Consistency
Rev Growth20x
Rev Trend60%
Revenue Consistency
All Time
Score
Net Growth80.56%
Net Trend31%
Net Income Consistency
Rev Growth169x
Rev Trend64%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Redhill Biopharma Ltd has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. RDHL does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 0.42—
1 Year2025-10-22
$ 1.74-75.74%
5 Years2021-10-22
$ 5.82K-99.99%
10 Years2016-10-21
$ 13.76K-100.00%
All Time2013-01-07
$ 11.1K-100.00%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 2M-$ 2M$ 3M
2025$ 286K-$ 429K$ 3M
2024$ 8M-$ 8M$ 4M
2023$ 6M$ 23M$ 6M
2022$ 61M-$ 71M$ 19M
2021$ 85M-$ 97M$ 38M
2020$ 64M-$ 76M$ 29M
2019$ 6M-$ 42M$ 47M
2018$ 8M-$ 38M$ 53M
2017$ 4M-$ 45M$ 46M
2016$ 101K-$ 29M$ 66M
2015-$ 21M$ 58M
2014$ 7M-$ 10M$ 22M
IPO2013$ 12K-$ 10M$ 12M
RDHL - Redhill Biopharma Ltd logo

Redhill Biopharma Ltd fundamental performance

Between 2020 and 2025, revenue declined from $ 64M to $ 286K and net income went from -$ 76M to -$ 429K. Revenue increased in 2 of those 5 years; net income in 3.

Between 2015 and 2025, net income went from -$ 21M to -$ 429K. Revenue increased in 6 of those 10 years; net income in 4.

Redhill Biopharma Ltd currently holds a 5-year HDB Score of 5.1 out of 10. How the HDB Score is calculated.

Membership

Explore RDHL with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies